Currently, the FDA has approved three GLP-1 RAs for obesity treatment: liraglutide, semaglutide and tirzepatide
357 This outcome may be attributed to the short treatment duration, which was insufficient to sustain beneficial hemodynamic effects
Accordingly, we encourage the adoption of GLP-1RA plus SGLT2i combination therapy in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (i.e., age 55 years, overweight/obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria)
S2CID 28038786
and dinner of baked salmon with roasted broccoli and sweet potato
Contraindications include increased bleeding, a history of medication hypersensitivity, lumbar puncture, and spinal anesthesia (10)